This executive summary of the ASAM 2020 update of clinical practice guidelines for treating opioid use disorder (OUD) is intended for clinicians who assess patients for OUD and prescribe medications, other health care providers, medical educators, and clinical care managers.
This discussion paper from researchers affiliated with the National Academy of Medicine identifies strategies to increase access to evidence-based treatment for opioid use disorder (OUD) in health care settings. Effective OUD treatment includes access to medications such as methadone, buprenorphine, or extended-release naltrexone as well as opportunities to receive additional services such as behavioral counseling, case management, and peer support.
The U.S. Department of Health and Human Services has prioritized expanding access to medication assisted treatment (MAT) for opioid use disorder (OUD) as an evidence-based treatment. Because many individuals with OUD are Medicaid beneficiaries, this U.S. Governmental Accountability Office report looked at state Medicaid policies and state and federal laws that might act as a barrier to Medicaid patients accessing MAT.
This case study profiles how a federally qualified health center (FQHC) in New York provides integrated medical and behavioral health care services for individuals with opioid addiction.
A link to the Get Waivered website which helps clinicians obtain Drug Enforcement Administration -X waivers to prescribe buprenorphine for opioid use disorder (OUD). They provide free waiver training as well as support for creating buprenorphine programs in emergency departments and strategies from the field of behavioral economics to help departments adopt new practices to treat OUD.
A comprehensive report on increasing access to evidence-based treatments for substance use disorder in the criminal justice and child welfare systems from researchers at the Addiction & Public Policy Initiative of the O’Neill Institute for National and Global Health Law at Georgetown Law Center. The report specifically addresses increasing access to medications to treat opioid use disorder (MOUD) in jails and prisons, in treatment court settings, and in the child welfare system. The report reviews programs in multiple states and summarizes legal, legislative and fiscal strategies to implement and manage evidence-based, public-health focused interventions in these settings.
This 2019 systematic review assesses the evidence for the effectiveness of behavioral health interventions as part of a medication-assisted treatment (MAT) regimen for opioid use disorder (OUD). The report also evaluates clinical practice guideline recommendations for behavioral health treatments as a part of MAT and describes 3 service delivery models that implement low-threshold MAT programs in Missouri, Virginia and in the Veterans Health Administration.
This 1-page patient guide focuses on safe use of methadone take home doses during the COVID-19 pandemic. Includes both English and Spanish language versions.
This memo outlines policies adopted by Montifiore Health System to continue patient access to buprenorphine treatment during the COVID-19 pandemic.
This 1-page guide from Montifiore Health Systems guides providers in prescribing buprenorphine during the COVID-19 pandemic. This information sheet discusses telemedicine best practices and changes in regulatory guidance during the pandemic,